教室紹介

2020年業績集

原著

  1. Waseda Y, Kobayashi S, Kanda E, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model. Clin Genitourin Cancer, 18(2): e62-70, 2020. PubMed

  2. Kijima T, Tanaka H, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy. Clin Genitourin Cancer, 18(4): 268-273.e2, 2020.PubMed

  3. Yoshida S, Takahara T, Ishii C, Arita Y, Waseda Y, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer. Clin Genitourin Cancer, 18(4): e391-e396, 2020.PubMed

  4. Tanaka H, Fukushima H, Kijima T, Nakamura Y, Yajima S, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer. Int J Urol, 27(3): 236-243, 2020.PubMed

  5. Fukushima H, Moriyama S, Waseda Y, Fukuda S, Uehara S, Tanaka H, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer. Eur Urol Focus, S2405-4569(20)30022-5, 2020.PubMed

  6. Fukushima H, Saito K, Yasuda Y, Tanaka H, Patil D, Cotta BH, Patel SH, Master VA, Derweesh IH, Fujii Y. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC). Clin Genitourin Cancer, 18(2):111-116.e1, 2020.PubMed

  7. Kijima T, Ito M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Treatment-induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropin-releasing hormone antagonists or agonists. Int J Urol, 27(4):354-355, 2020. PubMed

  8. Yoshida S, Taniguchi N, Moriyama S, Matsuoka Y, Saito K, Fujii Y. Application of virtual reality in patient explanation of magnetic resonance imaging-ultrasound fusion prostate biopsy. Int J Urol, 27(5):471-472, 2020.PubMed

  9. Fukushima H, Inoue M, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Incidence and Risk Factors of Hypertension Following Partial Nephrectomy in Patients With Renal Tumors: A Cross-sectional Study of Postoperative Home Blood Pressure and Antihypertensive Medications. Clin Genitourin Cancer, S1558-7673(20)30038-0, 2020.PubMed

  10. Nakamura Y, Yokoyama M, Yoshida S, Tanaka H, Kijima T, Ishioka J, Matsuoka Y, Saito K, Minami I, Yoshimoto T, Naito S, Ogawa Y, Yamada T, Uchida S, Fujii Y. Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome. Int J Urol, 27(5):395-400, 2020.PubMed

  11. Matsumoto S, Kijima T, Matsuoka Y, Yamamoto M, Fujii Y. A case of recurrent thrombocytopenia involving divergent immune-related mechanisms associated with pembrolizumab. Eur J Cancer, 131:104-107, 2020.PubMed

  12. Yokoyama M, Masuda H, Ito M, Waseda Y, Moriyama S, Toide M, Uchida Y, Uehara S, Kijima T, Yoshida S, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Longitudinal changes in patient-reported outcomes after artificial urinary sphincter implantation. Low Urin Tract Symptoms, doi:10.1111/luts.12311, 2020.PubMed

  13. Yoshida S, Takahara T, Arita Y, Toda K, Yoshimura R, Fujii Y. Patterns of failure after progressive site-directed therapy in oligo-progressive castration-resistant prostate cancer. Int J Urol, 27(7):634-635, 2020.PubMed

  14. Kaneko K, Yoshida S, Yamamoto K, Arita Y, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusion-weighted magnetic resonance imaging. Int J Urol, 27(7):599-604, 2020.PubMed

  15. Izumi K, Saito K, Nakayama T, Fukuda S, Fukushima H, Uehara S, Koga F, Yonese J, Kageyama Y, Fujii Y. Contact with renal sinus is associated with poor prognosis in surgically treated pT1 clear cell renal cell carcinoma. Int J Urol, 27(8):657-662., 2020.PubMed

  16. Matsuoka Y, Uehara S, Yoshida S, Tanaka H, Tanaka H, Kijima T, Yokoyama M, Ishioka J, Saito K, Fujii Y. Value of extra-target prostate biopsy for the detection of magnetic resonance imaging-missed adverse pathology according to the Prostate Imaging Reporting and Data System scores: Spatial analysis using magnetic resonance-ultrasound fusion images. Int J Urol, doi: 10.1111/iju.14281, 2020.PubMed

  17. Fukushima H, Fukuda S, Moriyama S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Fujii Y. Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report. Anticancer Drugs, 31(8):866-871, 2020.PubMed

  18. Cotta BH, Meagher MF, Patil D, Saito K, Patel SH, Patel DN, Miller N, Dutt R, Keiner C, Bradshaw AW, Wan F, Eldefrawy A, Yasuda Y, Fujii Y, Master V, Derweesh IH. Elevated Pre-operative C-reactive Protein Is Associated with Renal Functional Decline and Non-Cancer Mortality in Surgically Treated Renal Cell Carcinoma: Analysis from the INternational Marker Consortium for Renal Cancer [INMARC]. BJU Int, doi: 10.1111/bju.15200, 2020.PubMed

  19. Fujiwara M, Hayashi T, Takeda H, Yuasa T, Komai Y, Numao N, Yamamoto S, Fukui I, Kouno T, Yonese J. Cisplatin, Gemcitabine, and Paclitaxel as a Salvage Second-Line Therapy for Metastatic Germ-Cell Cancer. Clin Genitourin Cancer, S1558-7673(20)30122-1, 2020.PubMed

  20. Yajima S, Ooeda T, Inoue M, Suzuki H, Matsumoto S, Masuda H. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema (RS3PE), improved following surgical resection of prostatic carcinoma: A case report. Urol Case Rep, 32:101232. 2020.PubMed

  21. Kobayashi M, Yokoyama M, Inoue M, Fujii Y. Undifferentiated prostate cancer treated with docetaxel. IJU Case Rep, 3(4):125-127, 2020.https://doi.org/10.1002/iju5.12162

  22. Fujiwara M, Komai Y, Yuasa T, Numao N, Yamamoto S, Fukui I, Yonese J. Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high. IJU Case Rep, 3(2):62-64, 2020.PubMed

  23. Kijima T, Fukushima H, Kusuhara S, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Sakai Y, Saito K, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. Clin Genitourin Cancer. S1558-7673(20)30163-4, 2020.PubMed

  24. Kijima T, Yamamoto H, Saito K, Kusuhara S, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Sakai Y, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother, doi:10.1007/s00262-020-02709-2, 2020.PubMed

  25. Fukushima H, Kijima T, Fukuda S, Moriyama S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Saito K, Matsubara N, Numao N, Sakai Y, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study. Cancer Med, doi:10.1002/cam4.3445, 2020.PubMed